Focus On Execution Pays Off, Sets BMS Up For Growth In 2023
Sales Of Nine New Drugs Set To Double From 2022 Total
Revenue declined in 2022 but the company expects it to increase 2% this year, offsetting an anticipated $3.5bn drop in Revlimid sales as new launches generate $4bn in 2023.
